The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Background Guidelines recommend early initiation of multiple guideline-directed medical
therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and …

Novel pharmacologic treatment options reduce mortality and morbidity in a cost‐effective
manner in patients with heart failure (HF). Undisputedly, the effective implementation of …

Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences.
Despite various guidelines, no universally accepted consensus exists on best practices for …

Potassium (K+) is the most abundant cation in humans and is essential for normal cellular
function. Alterations in K+ regulation can lead to neuromuscular, gastrointestinal, and …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Aims Vericiguat reduced the primary composite outcome of cardiovascular death or heart
failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction …